Situation Report

BBC    By   Mark Doyle                                                                                                        Dec. 1, 2014

Tony Banbury declined to say if targets he had set in the fight against Ebola, to be achieved by Monday, had been met.

The targets were for the proportion of people being treated and for the safe burial of highly infectious bodies.

In October, Mr Banbury told the UN Security Council that by 1 December, "70% of all those infected by the disease must be under treatment and 70% of the victims safely buried if the outbreak is to be successfully arrested".

Mr Banbury said the 70% targets were being met in "the vast majority" of areas in the three worst-affected countries - Guinea, Sierra Leone and Liberia.

"But in some areas", he said, "including here in Sierra Leone - especially in the capital Freetown and in the town of Port Loko - we are falling short. And it is in those areas where we really need to focus our assets and our capabilities".

Read complete story

Description of efforts by the big drug companies to develop an Ebloa vaccine
THE NEW YORKER    By Vauhine Vara                        Nov. 25, 2014

"...why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson—three of the world’s biggest drug manufacturers? For years, pharmaceutical companies didn’t invest much in vaccines, partly because they were so costly and complicated to produce: they’re often made out of live bacteria, which are notoriously difficult to work with. But, over the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic-drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription-drug market. The World Health Organization estimates, based on various sources, that global vaccine sales rose from five billion dollars in 2000 to twenty-four billion dollars last year...."

Read complete article
http://www.newyorker.com/business/currency/race-ebola-vaccine

NBC NEWS    By Maggie Fox                                                                              Nov. 24, 2014

Two outbreaks, two entirely different outcomes. The World Health Organization has declared an outbreak of Ebola over in the Democratic Republic of Congo after just 66 cases and 49 deaths. It lasted three months.

Yet the epidemic in Liberia, Sierra Leone and Guinea’s been going for nine months, with more than 15,000 cases, 5,000 deaths and no end in sight.

What’s the difference? Experts say experience matters — it was the seventh outbreak in the former Zaire. But equally important is the fact that the village where it started was extremely remote, and the country has a rudimentary system of healthcare workers who know to look out for Ebola.

Read complete story

http://www.nbcnews.com/storyline/ebola-virus-outbreak/tale-two-outbreaks-why-congo-conquered-ebola-n253911

New research suggests that Ebola's deadly inflammatory effects may be caused by the result of protein shedding by infected cells. (Victor Volchkov / PLOS Pathogens)

CLICK HERE - RESEARCH - PLOS Pathogens - Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability

latimes.com - by Monte Morin - November 20, 2014

New research suggests that the massive and destructive inflammation that characterizes Ebola virus disease may be caused by the release of foreign proteins from infected cells.

Although Ebola is infamous for causing bleeding in some of its victims, doctors say the vast majority of deaths are the result of organ failure and shock brought on by the uncontrolled release of cytokines, compounds that cells use to communicate with one another and control immune response. . .

. . . In a paper published Thursday in Plos Pathogens, researchers at the Claude Bernard University of Lyon, in France, argued that glycoprotein shedding by infected cells may explain the immune system's damaging response.